NZX regulator reviewing Pacific Edge disclosure
After initial denial, capital raise reveals strong demand for biotech's stock.
NBR staff
Fri, 24 Sep 2021
NZX market regulator NZ RegCo is looking further into disclosures made by cancer diagnostics company Pacific Edge ahead of its announcement of a $80 million capital raise yesterday.
Last week Pacific Edge denied it was raising capital after information posted to the ASX as part of its planned
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
NBR staff
Fri, 24 Sep 2021
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
